Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma

Summary

This study is a double-blind, parallel-group, randomized study of active drug vs placebo in asthma.

Timeline

Start

2021-10-18

Primary completion

2023-03-29

Completion

2023-04-04

Outcome

Missed primary endpoint

Stopped (Business): “Strategic decision to discontinue the study based on adjusted clinical development plan. This decision is not based on any safety concerns.”

registry analysis (other test); Zavegepant vs Placebo; Least square mean difference -9.8 (95% CI -24.5 to 5.0) NCT04987944 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Zavegepant	Small molecule	150 mg	Oral

Indications